CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
Prospects and challenges for expert evidence at the UPC
However, expert evidence on economic issues is likely to become increasingly important for UPC proceedings in the near term. CRA consultants Andrew Tepperman,...